Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for the Prevention of Episodic Migraine
NCT06047457Phase 3Active, not recruiting
- Sponsor
- Ipsen
- Start
- Sep 2023
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of abobotulinumtoxinA in episodic migraine (4 arms), sponsored by Ipsen. Primary endpoint: Change from baseline in monthly migraine days at 24 weeks. Started Sep 2023; status: active, not recruiting.
02
Drugs
abobotulinumtoxinA
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT06047457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047457.